Fasting Insulin Levels: What They Mean, Optimal Ranges, and How to Improve Them

What a Fasting Insulin Test Measures

Insulin is a hormone produced by the beta cells of the pancreas. Its primary role is signaling cells to take up glucose from the bloodstream after eating. In a healthy person, insulin rises after a meal, drives glucose into cells, and then falls back to a low baseline. A fasting insulin test measures the amount of insulin circulating in the blood after an overnight fast of 8 to 12 hours, when no food-driven insulin secretion should be occurring.

This baseline level reflects how hard the pancreas is working just to maintain normal blood sugar in the resting state. When cells become resistant to insulin's signal (a condition called insulin resistance), the pancreas compensates by producing more insulin. Fasting insulin rises accordingly. Gerald Reaven described this compensatory relationship in his landmark 1988 Banting Lecture, where he proposed that insulin resistance and the resulting hyperinsulinemia sit at the center of a cluster of metabolic abnormalities including glucose intolerance, hypertension, and dyslipidemia (Reaven, Diabetes, 1988; PMID 3056758).

The key insight is that fasting insulin can be elevated long before fasting glucose crosses into the prediabetic range. The pancreas can maintain normal glucose for years by simply making more insulin. This silent hyperinsulinemia phase represents a window where metabolic damage is accumulating but standard blood work looks reassuringly normal. An Insulin Resistance Panel that includes fasting insulin, glucose, and HOMA-IR together provides the most useful baseline.

Normal vs. Optimal Fasting Insulin Ranges

Most laboratory reference ranges list "normal" fasting insulin as approximately 2.6 to 24.9 μU/mL (or similar, depending on the lab). These ranges are derived from population distributions and include many people who already have some degree of insulin resistance. A "normal" result on a lab report does not necessarily mean optimal.

Studies in lean, healthy, insulin-sensitive populations paint a different picture. A study of 1,434 healthy nondiabetic Chinese men found a reference interval of 1.57 to 16.32 μU/mL with a median of 5.79 μU/mL (Li et al., Singapore Med J, 2012; PMID 23268156). The Tehran Lipid and Glucose Study, which carefully screened 309 non-obese healthy adults, established 95% reference values of 2.11 to 12.49 μU/mL for the total population (Tohidi et al., Clin Biochem, 2014; PMID 24530467). In both studies, the medians for healthy individuals clustered between 4 and 7 μU/mL.

Many clinicians focused on metabolic optimization consider fasting insulin below 5 to 6 μU/mL as optimal, though no single universal cutoff exists. The general pattern from the research: medians in carefully screened healthy populations tend to fall in the 4 to 7 μU/mL range, levels above 10 to 12 μU/mL consistently correlate with increased insulin resistance in studies using euglycemic clamp validation, and levels above 15 to 20 μU/mL (even if within some lab "normal" ranges) are associated with meaningful metabolic risk.

One important caveat: insulin assays are not standardized. A comparison of eight commercially available insulin assays found that the lowest and highest median values differed by a factor of 1.8 across assays (Tohidi et al., Scand J Clin Lab Invest, 2017; PMID 28150502). This means the same blood sample could produce meaningfully different numbers depending on the lab's assay platform. When tracking fasting insulin over time, using the same lab and assay method is essential for meaningful comparison.

What Elevated Fasting Insulin Means

An elevated fasting insulin level, in the context of normal fasting glucose, is a signal that insulin resistance has developed but the pancreas is still able to compensate. The body is maintaining glucose control, but only by flooding the system with extra insulin. This compensatory hyperinsulinemia is not benign.

Shanik et al. reviewed evidence from animal models, clinical studies, and insulinoma patients and concluded that hyperinsulinemia is not merely a passive consequence of insulin resistance but can itself drive and sustain resistance through receptor downregulation and post-receptor signaling defects (Shanik et al., Diabetes Care, 2008; PMID 18227495). In mice with extra copies of the insulin gene that produced 2 to 4 times normal basal insulin, insulin resistance, hyperglycemia, and hypertriglyceridemia developed even at normal weight.

Crofts et al. analyzed the Kraft database of 14,384 oral glucose tolerance tests with concurrent insulin measurements collected from the 1970s through 1990s. Among participants with completely normal glucose tolerance, 54% of the total cohort (n=4,185) still showed normal glucose. But of these glucose-normal individuals, over half (n=2,079) displayed hyperinsulinemic patterns despite clearing glucose normally (Crofts et al., Diabetes Res Clin Pract, 2016; PMID 27344544). Their glucose looked fine. Their insulin told a different story.

Notably, the Crofts analysis also found that fasting insulin alone had "limited value" in diagnosing hyperinsulinemia compared to the dynamic insulin patterns during a glucose tolerance test. This is an important limitation: a normal fasting insulin does not entirely rule out insulin resistance, particularly the early, postprandial-predominant forms. But an elevated fasting insulin is a strong signal that resistance has become substantial enough to affect baseline pancreatic output.

Fasting Insulin and Disease Risk

Reaven's 1988 Banting Lecture outlined the concept now known as metabolic syndrome: insulin resistance driving a cluster of abnormalities that increase cardiovascular and diabetes risk. He noted that approximately 25% of nonobese individuals with normal glucose tolerance are insulin resistant, and that the compensatory hyperinsulinemia needed to maintain glucose control carries its own consequences, including hypertension, elevated triglycerides, low HDL, and accelerated atherosclerosis (Reaven, Diabetes, 1988; PMID 3056758).

A 2017 meta-analysis by Zhang et al. pooled data from seven prospective studies involving 26,976 non-diabetic adults to evaluate whether elevated fasting insulin and HOMA-IR predict mortality. Comparing the highest versus lowest category, elevated HOMA-IR was associated with a 34% increased risk of all-cause mortality (RR 1.34, 95% CI 1.11-1.62, p=0.002) and a 2.11-fold increased risk of cardiovascular mortality (95% CI 1.01-4.41, p=0.048). For fasting insulin alone, the association with all-cause mortality was borderline (RR 1.13, 95% CI 1.00-1.27, p=0.058), which the authors noted may reflect the limited number of studies rather than a true absence of risk (Zhang et al., Biosci Rep, 2017; PMID 28811358).

The Diabetes Prevention Program (DPP), one of the most important clinical trials in metabolic medicine, enrolled 3,234 adults with elevated fasting and post-load glucose (prediabetes). Lifestyle intervention targeting 7% weight loss and 150 minutes per week of physical activity reduced the incidence of type 2 diabetes by 58% compared to placebo. Metformin reduced incidence by 31%. The number needed to treat with lifestyle intervention to prevent one case of diabetes over three years was just 6.9 people (Knowler et al., N Engl J Med, 2002; PMID 11832527). While the DPP measured glucose as its primary endpoint, the improvements in diabetes incidence were driven by improvements in the underlying insulin resistance and beta-cell compensation.

The Finnish Diabetes Prevention Study similarly randomized 522 overweight subjects with impaired glucose tolerance to lifestyle intervention or control. The intervention group lost an average of 4.2 kg in year one and reduced diabetes incidence by 58% over a mean follow-up of 3.2 years (Tuomilehto et al., N Engl J Med, 2001; PMID 11333990). The consistency of the 58% risk reduction across both trials, conducted independently on different continents, is striking.

How Fasting Insulin Relates to HOMA-IR

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) combines fasting insulin with fasting glucose into a single index. The formula is straightforward: HOMA-IR = (fasting insulin in μU/mL × fasting glucose in mg/dL) / 405. It was developed by Matthews et al. in 1985 and validated against the euglycemic clamp, the gold standard for measuring insulin resistance. The original validation showed a correlation of Rs = 0.88 (p < 0.0001) between HOMA-IR and clamp-derived insulin resistance (Matthews et al., Diabetologia, 1985; PMID 3899825).

The advantage of HOMA-IR over fasting insulin alone is that it accounts for the feedback loop between insulin and glucose. A fasting insulin of 10 μU/mL means something different when fasting glucose is 80 mg/dL (HOMA-IR = 1.98, likely acceptable) versus when fasting glucose is 105 mg/dL (HOMA-IR = 2.59, suggesting meaningful resistance). The Zhang et al. meta-analysis found HOMA-IR to be a stronger predictor of mortality than fasting insulin alone, consistent with this added signal from the glucose component.

For a comprehensive assessment, the HOMA-IR test calculates this index from a single fasted blood draw. Many clinicians consider HOMA-IR below 1.0 as optimal, below 1.5 as normal, 1.5 to 2.5 as early insulin resistance, and above 2.5 as significant insulin resistance, though exact cutoffs vary by population. For a broader metabolic picture, the Insulin Resistance Panel combines fasting insulin, fasting glucose, and HOMA-IR alongside hemoglobin A1c.

How to Prepare for a Fasting Insulin Test

Fasting insulin requires an 8 to 12 hour overnight fast. Water is fine (and encouraged) during the fasting period. Avoid food, caloric beverages, coffee, and alcohol during the fast. The test is ideally drawn in the morning.

Certain factors can affect results beyond the fasting state. Acute stress, poor sleep the night before, and recent intense exercise can all transiently affect insulin levels. For the most representative result, draw the test after a typical night's sleep, avoid unusually strenuous exercise the day before, and note any medications you take (corticosteroids, thiazide diuretics, and certain other drugs can raise insulin levels). If you are tracking insulin over time, try to keep the conditions roughly consistent between draws: same lab, similar time of morning, similar fasting duration.

How to Lower Fasting Insulin Levels

The evidence base for reducing fasting insulin centers on lifestyle changes that improve insulin sensitivity. The DPP and Finnish DPS trials provide the strongest evidence: moderate weight loss (5-7% of body weight) combined with regular physical activity (150 minutes per week of moderate-intensity exercise like brisk walking) reduced diabetes incidence by 58% in both trials, with improvements in insulin sensitivity driving the benefit (Knowler et al., 2002; Tuomilehto et al., 2001).

Exercise improves insulin sensitivity through multiple mechanisms. Muscle contraction activates glucose uptake through pathways that are independent of insulin signaling (GLUT4 translocation via AMPK activation). Both aerobic exercise and resistance training have demonstrated benefits. A meta-analysis of vegetarian diet combined with aerobic exercise found a mean reduction in HOMA-IR of -0.75 (95% CI -1.08 to -0.42), representing a clinically meaningful improvement in insulin sensitivity (Long et al., Eat Weight Disord, 2023; PMID 36790517).

Dietary strategies with evidence for lowering fasting insulin include: reducing refined carbohydrates and added sugars (which directly stimulate insulin secretion), increasing dietary fiber (the DPP lifestyle arm targeted increased fiber intake), and prioritizing whole foods over processed ones. Time-restricted eating (limiting food intake to a defined daily window) has shown promise in some trials for improving insulin sensitivity, though the evidence is still developing and the effects may be partly mediated by caloric reduction.

Insulin sensitivity can respond relatively quickly to lifestyle changes. Improvements in insulin-mediated glucose uptake have been measured within days of starting regular exercise, even before significant weight loss occurs. However, sustained improvements require sustained behavior changes. The DPP lifestyle group maintained meaningful risk reduction over the full 2.8-year average follow-up, but only while participants maintained their activity and weight targets.

Tracking Your Progress

Fasting insulin is a useful metric for monitoring the effectiveness of lifestyle interventions over time. Because insulin sensitivity can improve relatively quickly with exercise and dietary changes, retesting every 3 to 6 months provides enough time to see meaningful shifts while keeping the feedback loop tight enough to maintain motivation.

When tracking, keep the assay variable in mind: always use the same lab for serial measurements, since different immunoassays can produce values differing by up to 1.8-fold for the same sample (Tohidi et al., 2017). Look at the trend direction rather than fixating on a single number. A fasting insulin that drops from 14 to 9 μU/mL over six months of consistent exercise and dietary changes represents a meaningful improvement in insulin sensitivity, regardless of whether you have crossed a specific threshold.

Pairing fasting insulin with fasting glucose to calculate HOMA-IR adds context. And combining these with hemoglobin A1c, which reflects average glucose over the prior 2 to 3 months, provides a more complete metabolic picture. The goal is not a single perfect number but a clear trajectory toward better insulin sensitivity, confirmed by multiple markers moving in the right direction.